EXPIRED
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
Epidemiology of Drug Abuse (R03)
R03 Small Grant Program
Reissue of PA-11-232
PA-15-002
93.279
This Funding Opportunity Announcement (FOA) is intended to support research projects to enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, abuse, and addiction across individuals, families, communities, and diverse population groups. This FOA strongly encourages applications that reflect the breadth of epidemiology research by addressing multiple levels of risk, resilience, and causation across scientific disciplines; by applying novel methods to advance knowledge of the interplay among genetic, environmental, and developmental factors and between social environments and associated health and disease outcomes; and by building on the research investments of NIH and sister HHS agencies to harness existing data on the epidemiology and etiology of drug abuse to improve public health prevention and treatment programs.
October 3, 2014
January 16, 2015
Not applicable
Standard dates apply or Month(s) Day(s), Year(s), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Standard AIDS dates apply. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Standard dates apply
Standard dates apply
Standard dates apply
New Date January 8, 2018 per issuance of NOT-DA-17-031. (Original Expiration Date: September 8, 2017)
Not Applicable
Required Application Instructions
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission
Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
The NIH R03 funding opportunity announcement (FOA) supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
The mission of NIDA’s Epidemiology Research Program is to promote, advance, and disseminate novel epidemiologic research that examines the impact of individual, familial, behavioral, developmental, and sociocultural/environmental risk and protective factors related to drug use, abuse, and addiction. This Program supports a broad portfolio of research to fill gaps in our knowledge of the continually changing patterns of drug use, associated factors, and consequences in populations, including, but not limited to, studies that examine:
(1) Individual, familial, and environmental factors associated with drug use;
(2) Interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistence/recovery, and relapse;
(3) Co-occurring psychiatric conditions, behaviors and associated problems;
(4) Indicators and mechanisms of risk, vulnerability, and health disparities among and between subpopulations;
(5) Developmental and life course trajectories related to the etiology and natural history of drug use;
(6) Need for, access to, and utilization of drug abuse prevention and treatment services, and the social, community, and organizational factors that influence intervention development, availability, and effectiveness.
(7) Public health impacts of the attitudes, availability, behaviors, and products, resulting from the shifting marijuana policy environment
This FOA encourages applications that build upon an existing Program, giving highest priority to projects addressing the breadth of risk (and protective factors) to identify causal risk factors, dynamic multilevel interactions, and to projects that seek mechanistic explanations for substance abuse outcomes, reflecting the multiple levels of drug abuse epidemiology research. This includes projects that are transdisciplinary in nature and apply novel methods that allow for the advancement and translation of science, such as utilization of systems science methodologies (e.g., agent based modeling, system dynamics modeling, network analysis) or geographic information systems (GIS), as well as those that take advantage of the investments made by NIH and other funders by using existing data to inform our understanding of drug abuse epidemiology and etiology in a creative and cost efficient manner. Of particular interest are studies that efficiently combine the advantages of epidemiologic samples with laboratory-based, biological, and genetic measures, and that address gender differences and health disparities, as well as projects that have the ability to identify and rapidly disseminate information about newly emerging drug trends. Supported research will have substantial public health impact and will inform basic/clinical, prevention, and services research to reduce the burden of drug use, abuse, and addiction on the nation's health.
In addition to the areas of specific priority noted above, other program areas of particular interest include but are not limited to the following:
Emerging & Current Drug Abuse Trends
Studies that assess and examine rates (e.g., prevalence, incidence), emerging and current patterns and transitions (e.g. prescription opioid abuse to heroin), cycles, and trends of drug use, abuse, addiction, morbidity, mortality and associated social and behavioral consequences (e.g., crime, violence, sexually transmitted infections such as HIV, and other comorbidities) in general and defined populations, with special attention to health disparities issues including racial/ethnic and sexual minorities. Applicants proposing to study emerging drugs and trends are encouraged to consider exploring opportunities and efficiencies which may be presented by existing infrastructures such as the National Drug Early Warning Network System (NDEWS).
This includes studies:
*Evaluating the impact of new policies and technologies, such as abuse-deterrent opioid formulations or cannabis delivery devices, on prevalence of drug use and associated consequences;
*Utilizing social media data or other data collected from the Internet and mobile technologies to assess epidemiologic and risk behavior patterns;
*Developing innovative methods for the early identification of use of novel synthetic psychoactive substances;
*Assessing the utility and validity of innovative methods for population-based monitoring of drug abuse trends (e.g. wastewater analysis);
*Identifying the nature and extent of emerging drug use patterns within local, national, and international contexts (as they can inform Nationally relevant questions), including studies of social, cultural, and behavioral factors that influence patterns of use and availability.
Natural History
Studies on the onset, progression, and outcomes of drug abuse and addiction in population based samples, including research:
*Evaluating public health outcomes of addiction over the life course including among the elderly;
*Examining drug use-related risk factors associated with the acquisition and transmission of HIV, HCV, HBV, and other infections with an eye toward intervention;
*Assessing the behavioral, health, and social correlates of disease acquisition and progression.
Etiology/Developmental Trajectories
Studies of the origins and trajectories of drug use, abuse, and addiction that build upon and expand beyond the large body of extant descriptive research, including studies:
*Identifying the individual-, familial-, and community-level risk and protective factors and their interactions and applying techniques that help distinguish correlates and markers of risk from causal risk factors and illuminating possible points of intervention in the trajectories to addiction for vulnerable individuals;
*Advancing the understanding of the interplay among precursor, comorbid, and resulting psychiatric and/or physiological disorders and drug abuse, with particular interest in the role of associated comorbidities in the risk for drug abuse (e.g. subtypes of childhood attention deficit hyperactivity disorder), and the interplay between internalizing disorders and drug abuse;
*that inform understanding of risk trajectories by applying methods to study gene-environment interplay, including strong and well-justified studies of gene-environment interactions and correlations;
*Examining factors associated with transitions in drug using behaviors (risk, initiation, regular use, addiction, recovery, relapse), in particular those leading towards and away from persistent drug use at all stages but especially in early and mid-adulthood, with emphasis on socio-cultural and environmental factors, genetic factors, and co-morbidity.
Social and Legal Epidemiology
Studies of the dynamic multi-level interaction among social environmental and other factors and how they influence (facilitate or mitigate) drug use, abuse, and addiction, including research:
*Conducting quasi-natural experiments to understand the effects of changing federal, state, or local laws, regulations and policies on the epidemiology of cannabis, alcohol, tobacco, prescription drug or other drug use and abuse;
*Assessing and addressing the proliferation of edible marijuana products and other novel modes of consumption;
*Evaluating driving risks and behaviors under the influence of drugs other than alcohol, including studies of the effects of drugs on driving performance at different levels of drug involvement among demographically diverse populations;
*Investigating the extent to which social environment characteristics interact with biological/physiological pathways;
*Identifying the intermediate structural characteristics of macro-level social environments (e.g. social networks and norms, markets, institutional characteristics of school, prisons, etc.).
Methods & Measurement
Innovative statistical, genetic, or systems science methods and measurement, including research:
*Applying innovative methods or techniques from other disciplines that are novel to drug abuse research, such as utilization of systems science methodologies (e.g., agent based modeling, system dynamics modeling, network analysis) or geographic information systems (GIS);
*Improving the accuracy, efficiency, scope, timeliness, and analysis of drug use, abuse, and addiction epidemiologic data and research in areas described above, including projects that facilitate small sample estimation;
*Developing novel methodologies to improve the accuracy, efficiency, scope, timeliness, and analytic yield of epidemiologic data on drug abuse and inter-related health and social problems (e.g., HIV/AIDS, psychiatric comorbidity, poly-substance use, violence) particularly in hard to reach or underrepresented populations.
Cross-cutting Topics
The Program areas discussed above should be considered in the context of a number of cross-cutting topics like HIV/STIs, comorbidities, familial/genetic liability and secondary data analysis. Given that drug use behaviors are associated with risks for the acquisition and transmission of infectious diseases, including HIV/AIDS, other sexually transmitted infections (STIs), Hepatitis (HCV and HCB), and Tuberculosis (TB), researchers are encouraged to consider these across all the Program areas.
Similarly, drug use and abuse should be considered in the context of other physical and psychiatric comorbidities and interactions. The Program also encourages research on familial/genetic liability and vulnerability, as well as research on developmental processes and sequelae as they relate to drug use, abuse, and addiction across childhood, adolescence, and early to late adulthood.
Lastly, secondary analysis of existing data provides unique opportunities to answer innovative questions about the complex nature and course of drug abuse for relatively low cost, therefore analysis of existing data in all Program areas is strongly encouraged (also see PAR-13-080). Combining existing samples to enhance power and analytical ability to study lower base rate risk factors, subpopulations, or outcomes is particularly encouraged, along with innovative methods for data harmonization.
NIDA Special Considerations
HIV/AIDS Counseling and Testing Policy for the National Institute on Drug Abuse: In light of recent significant advances in rapid testing for HIV and in effective treatments for HIV, NIDA has revised its 2001 policy on HIV counseling and testing. NIDA-funded researchers are strongly encouraged to provide and/or refer research subjects to HIV risk reduction education and education about the benefits of HIV treatment, counseling and testing, referral to treatment, and other appropriate interventions to prevent acquisition and transmission of HIV. This policy applies to all NIDA funded research conducted domestically or internationally. For more information see https://grants.nih.gov/grants/guide/notice-files/NOT-DA-07-013.html.
National Advisory Council on Drug Abuse Recommended Guidelines for the Administration of Drugs to Human Subjects: The National Advisory Council on Drug Abuse (NACDA) recognizes the importance of research involving the administration of drugs with abuse potential, and dependence or addiction liability, to human subjects. Potential applicants are encouraged to obtain and review these recommendations of Council before submitting an application that will administer compounds to human subjects. The guidelines are available on NIDA's Web site at http://www.drugabuse.gov/funding/clinical-research/nacda-guidelines-administration-drugs-to-human-subjects.
Points to Consider Regarding Tobacco Industry Funding of NIDA Applicants: The National Advisory Council on Drug Abuse (NACDA) encourages NIDA and its grantees to consider the points it has set forth with regard to existing or prospective sponsored research agreements with tobacco companies or their related entities and the impact of acceptance of tobacco industry funding on NIDA's credibility and reputation within the scientific community. Please see http://www.drugabuse.gov/about-nida/advisory-boards-groups/national-advisory-council-drug-abuse-nacda/council-statements/points-to-consider-regarding- for details.
Data Harmonization for Substance Abuse and Addiction via the PhenX Toolkit: NIDA strongly encourages investigators involved in human-subjects studies to employ a common set of tools and resources that will promote the collection of comparable data across studies and to do so by incorporating the measures from the Core and Specialty collections, which are available in the Substance Abuse and Addiction Collection of the PhenX Toolkit (www.phenxtoolkit.org). Please see NOT-DA-12-008 (https://grants.nih.gov/grants/guide/notice-files/NOT-DA-12-008.html) for further details.
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
New
Resubmission
Revision
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Direct costs are limited to $100,000 direct costs over the 2-year period, with no more than $50,000 in direct costs allowed in a single year.
The maximum project period is 2 years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Governments
Other
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to
apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Applicant Organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Program Director(s)/Principal
Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple
Program Director/Principal Investigator Policy and submission details in the Senior/Key
Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:
In addition, the NIH will not accept a resubmission (A1) application that is submitted later than 37 months after submission of the new (A0) application that it follows. The NIH will accept submission:
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.:
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide.
When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date. If a Changed/Corrected application is submitted after the deadline, the application will be considered late.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
Important
reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the
Credential field of the Senior/Key Person Profile Component of the
SF424(R&R) Application Package. Failure to register in the Commons
and to include a valid PD/PI Commons ID in the credential field will prevent
the successful submission of an electronic application to NIH. See Section III of this FOA for information on
registration requirements.
The applicant organization must ensure that the DUNS number it provides on the
application is the same number used in the organization’s profile in the
eRA Commons and for the System for Award Management. Additional information may
be found in the SF424 (R&R) Application Guide.
See more
tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Applications that are incomplete will not be reviewed.
Applicants are required to follow our Post Submission Application Materials policy.
Important Update: See NOT-OD-16-006 and NOT-OD-16-011 for updated review language for applications for due dates on or after January 25, 2016.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
For this particular announcement, note the following:
The R03 small grant supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding. Because the research project usually is limited, an R03 grant application may not contain extensive detail or discussion. Accordingly, reviewers should evaluate the conceptual framework and general approach to the problem. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or from investigator-generated data. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Investigator(s)
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be
managed?
If the project involves human subjects and/or NIH-defined clinical research,
are the plans to address 1) the protection of human subjects from research
risks, and 2) inclusion (or exclusion) of individuals on the basis of
sex/gender, race, and ethnicity, as well as the inclusion or exclusion of
children, justified in terms of the scientific goals and research strategy
proposed?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or
more of the six categories of research that are exempt under 45 CFR Part 46,
the committee will evaluate: 1) the justification for the exemption, 2) human
subjects involvement and characteristics, and 3) sources of materials. For
additional information on review of the Human Subjects section, please refer to
the Guidelines
for the Review of Human Subjects.
Inclusion of Women, Minorities, and Children
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
Renewals
Not Applicable
Revisions
For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Applications from Foreign Organizations
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications . Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH Grants
Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided
to the applicant organization for successful applications. The NoA signed by
the grants management officer is the authorizing document and will be sent via
email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection
of an application for award is not an authorization to begin performance. Any
costs incurred before receipt of the NoA are at the recipient's risk. These
costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and
conditions found on the Award
Conditions and Information for NIH Grants website. This includes any
recent legislation and policy applicable to awards that is highlighted on this
website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Cooperative Agreement Terms and Conditions of Award
Not Applicable
When multiple years are involved, awardees will be required to submit the annual Non-Competing Progress Report (PHS 2590 or RPPR) and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
eRA Service Desk (Questions regarding ASSIST, eRA Commons registration, submitting and tracking an application, documenting system
problems that threaten submission by the due date, post submission issues)
Telephone: 301-402-7469 or 866-504-9552 Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
Finding Help Online: https://grants.nih.gov/support/index.html
Email: commons@od.nih.gov
Grants.gov Customer Support (Questions
regarding Grants.gov registration and submission, downloading forms and
application packages)
Contact Center Telephone: 800-518-4726
Web ticketing system: https://grants-portal.psc.gov/ContactUs.aspx
Email: support@grants.gov
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Telephone: 301-945-7573
Email: GrantsInfo@nih.gov
Marsha F. Lopez, Ph.D., M.H.S.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504
Email: lopezmar@nida.nih.gov
Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).
Suzette Epps
National Institute on Drug Abuse (NIDA)
Telephone: 301-490-7431
Email: eppss@mail.nih.gov
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.